Pyrrole fused-ring pyrazole compounds have been prepared by Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. and characterized as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.